Mounjaro cost in 2026: one cash price for every dose
Without insurance, Mounjaro costs $499 a month at every strength from 2.5 to 15 mg through LillyDirect or TrumpRx; the list price is $1,112.
Mounjaro is tirzepatide for type 2 diabetes, the same molecule as Zepbound, sold by Eli Lilly as a carton of four weekly single-dose pens. Its self-pay price, listed on TrumpRx and routed to Lilly, is $499 a month whatever the strength, from the 2.5 mg starting pens to 15 mg, which makes it $50 more a month than Zepbound vials at 7.5 mg and above. The list price is $1,112 per carton and pharmacies pay about $1,077 according to the NADAC survey. Medicare Part D covers Mounjaro for diabetes and for cardiovascular risk in diabetes; under the 2026 standard benefit, your share at list price reaches the $2,100 cap in June and stops there. Mounjaro has no Medicare negotiated price and is not in the GLP-1 Bridge.
The whole of 2026, by way of paying
- Paying cash (self-pay)$5,988
- Medicare Part D, covered use$2,100
- Medicaid, at a $4.00 copay$48
You would pay, Mounjaro 7.5 mg
$499 / month
$5,988 in 2026
Self-pay price published by LillyDirect / TrumpRx, the same through both.
Same dose, other ways to pay (per month)
- List price (wholesale acquisition cost)$1,112
- Self-pay: LillyDirect or TrumpRx$499
- What pharmacies pay (NADAC)$1,077
- Medicare Part D, your share (month avg., 2026)$175
TrumpRx and makers read on October 16, 2026 · NADAC file of October 14, 2026. Estimate only, not medical advice. How it is calculated
Prices read by Radif Partners · Editorial policy · Method and data
Flat pricing, and the Zepbound comparison people make
All six Mounjaro strengths cost the same in cash. Raising the dose by 2.5 mg every four weeks, as the label allows, therefore changes nothing on the bill. The question most readers bring is a different one: Zepbound contains the same active substance and costs less in cash. The two products are approved for different conditions, diabetes for Mounjaro and weight reduction or sleep apnea for Zepbound, and insurers, Medicare included, cover them by indication. A cash price comparison does not make them interchangeable for a given patient.
| Strength | Self-pay a month | List price | Pharmacy cost (NADAC) |
|---|---|---|---|
| 2.5 mg | $499 | $1,112 | $1,077 |
| 5 mg | $499 | $1,112 | $1,077 |
| 7.5 mg | $499 | $1,112 | $1,077 |
| 10 mg | $499 | $1,112 | $1,077 |
| 12.5 mg | $499 | $1,112 | $1,077 |
| 15 mg | $499 | $1,112 | $1,077 |
Medicare Part D, month by month
A Part D enrollee on Mounjaro meets the $615 deductible with the first fill, then pays a quarter of the price of each later carton. Under the defined standard benefit that adds up to the $2,100 ceiling in June; the rest of the year costs nothing. The heavy months come first, which is what the Medicare Prescription Payment Plan smooths out by billing the same amount each month. In 2027 the cap rises to $2,400 and, with no negotiated price for tirzepatide, a full year at list price costs about $2,400.
With employer insurance
Commercial plans usually cover Mounjaro for type 2 diabetes with a prior authorization. With a plan that covers it, Lilly’s savings card lets you pay as little as $25, saving at most $150 a month and $1,950 a year until December 31, 2026; it is closed to government programs. A $250 copay becomes $100. If your plan denies coverage, the $499 self-pay price is the reference, and payments made that way do not count toward your deductible.